Antimalarial drug resistance in Southeast Asia is threatening the control and elimination of malaria, and drug makers can help, says a tropical medicine expert.
Catalent has partnered with US non-profit PATH for antibody discovery using the CDMO’s GPEx cell line platform, funded by PATH’s Malaria Vaccine Initiative (MVI).
A recently opened facility will double production of Sanofi Pasteur’s vaccine Stamaril which could alleviate shortages in the wake of recent yellow fever outbreaks in parts of Africa.
Sanofi Pasteur says Mexican approval for Dengvaxia vindicates the ‘industrial risk’ it took when it invested €350m in a dengue fever vaccine plant in 2009.
Concerns climate change will see malaria, West Nile virus and chikungunya spread to the UK are legitimate according to Public Health England, even though no insects carrying such diseases have been detected to date.
Fans heading to the World Cup in Brazil should consider getting vaccinated against yellow fever according to Public Health England (PHC), which says manufacturing problems at Sanofi Pasteur MSD will not restrict access.
Better data on the global burden of tick-borne illnesses may encourage profit driven drugmakers to spend their R&D budgets on much needed treatments says the WHO.
A push to root out antimalarial counterfeit drugs in Ghana will begin later this year or early 2014 as part of a pilot project to test an FDA-developed counterfeit detector.
Counterfeit ACT could support the spread of drug resistant malaria strains from South-East Asia, where chloroquine first became ineffective, to sub-Saharan Africa.
The Institute for OneWorld Health (iOWH) has moved one step closer to supplying a key component of a malaria treatment on an industrial scale as it revealed details of its latest activities to bring the ingredient to regions in short supply.
Almost half of antimalarials in Senegal are substandard, according to a USP study which will be used by local regulators to focus efforts on high-risk products, brands and geographies.
Quintiles has targeted Africa as the next non-traditional area to develop new medicines and the opening of its office in Ghana, which is now fully operational, is a major step in this process, Gillian Corken, head of Quintiles in Africa, told Outsourcing-Pharma.
Sanofi-aventis is has made its largest ever investment in its vaccine capacity, using €350m ($479m) to construct a dengue fever vaccine manufacturing plant in France.
A multinational, multidisciplinary initiative involving scientists,
public health workers, police and government officials could
provide a cogent model for rooting out and stamping out
counterfeiting of essential and lifesaving drugs.
Millions of malaria sufferers have been offered new hope after UK
scientists not only developed a new antibody against malaria, but
also a way to test it.
Novartis is utilising several innovative techniques to engender
feelings of trust and respect in emerging Asian markets. These
include researching locally endemic diseases and selling drugs at
cost price.
Australian contract manufacturing organisation (CMO) Eastland
Medical Systems has bagged a manufacturing and distribution
contract with UK's Proto-Pharma for its anti-malaria treatment.
Researchers believe that they have discovered a new treatment for
the severest form of Malaria, which may be able to help in
preventing the two million lives the disease claims each year.
GlaxoSmithKline (GSK) has asked vaccine developing firm Antigenics
to supply it with more of its QS-21 adjuvant as its vaccines
progress in the pipeline, while at the same the British drug giant
is pushing ahead with its own adjuvant,...
Determined to eradicate a disease that takes the lives of more than
one million people worldwide each year, Novartis has announced it
will participate in a new public-private partnership which aims to
discover more potent drugs to...
A research program has released a small molecule binding annotation
and comparison tool, which is expected to accelerate lead
development in antimicrobial drug discovery, as well as allow
chemists to develop safer, more specific...
According to a new report, the number of victims claimed by the
South-East Asian tsunami is likely to rise due to the lack of drugs
in active development for post-tsunami diseases. The report
identified only 87 drugs in active development...
A non-profit pharmaceutical company, the Institute for OneWorld
Health, has been awarded a $42.6 million (€32.1m)grant from the
Bill & Melinda Gates Foundation to find a new way of producing
a valuable drug for malaria, which...
A potential new drug target for malaria was revealed this week
after scientists discovered the structure and function of the
malaria parasite, Plasmodium falciparum, for the first time. The
findings represent a breakthrough for future...
Children around the world at risk of malaria took a step closer to
having a protective vaccine with the reporting of encouraging new
data on a candidate developed by GlaxoSmithKline Biologicals.
With the incidence of drug resistant tuberculosis (TB) and dengue
fever rapidly accelerating worldwide, Novartis has announced the
opening of a non-profit initiative in drug discovery focussing on
advanced biomedical research for...
New biotechnology processes are poised to change the economics of
manufacturing drugs, creating the potential for delivering both
affordable medicines to patients in the developing world and laying
the foundation for new markets.
Scientists have determined the structure of a key target enzyme for
novel drug development to treat infectious diseases, including
malaria and tuberculosis.
